http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Sunovion Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts
-
Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda® (lurasidone HCl) in the Treatment of Schizophrenia
-
Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
-
Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow® (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (C
-
Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression
-
Sunovion Announces Health Outcomes Data on Exacerbation-Related Hospitalizations that Support the Use of Brovana® (arfomoterol tartrate) Inhalation Solution in People with Moderate-to-Severe COPD at
-
American Thoracic Society (ATS) and Sunovion Release Landmark Survey of Pulmonologists’ Attitudes and Practices with Inhalation Devices for COPD at the ATS 2016 International Conference
-
Sunovion to Present Data on Latuda® (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association
-
Sunovion Presents New Health Outcomes Data Supporting Brovana® (arformoterol tartrate) Inhalation Solution in People with Moderate-to-Severe COPD at the 2016 American Thoracic Society (ATS) Internati
-
Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow® (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmon
-
Sunovion Announces Results of Health Outcomes Analyses Supporting the Use of Aptiom® (eslicarbazepine acetate) in People with Partial-Onset Seizures at the 68th American Academy of Neurology (AAN) An
-
Sunovion to Present Data Analyses Supporting Use of Aptiom® (eslicarbazepine acetate) at the 68th American Academy of Neurology (AAN) Annual Meeting
-
Valent BioSciences Corporation Reaches Global Licensing Agreement with LidoChem, Inc. for New Biocontrol Technology to Protect Against Nematodes
-
New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients
-
Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
-
Sunovion Announces Results of Health Outcomes Analyses Exploring the Effectiveness of Aptiom® (eslicarbazepine acetate) in People with Partial-Onset Seizures
-
Sunovion to Present New Research and Data Analyses Supporting Use of Aptiom® (eslicarbazepine acetate) at the American Epilepsy Society (AES) 69th Annual Meeting
-
Sunovion and the COPD Foundation Launch Reel COPD to Support Family Caregivers
-
Sunovion to Present Health Outcomes Data Supporting Brovana® (arformoterol tartrate) Inhalation Solution in Patients with COPD at the 2015 American College of Chest Physicians Annual Meeting
-
Sunovion Celebrates Five-Year Anniversary Milestone
-
'Heroes' Actor Greg Grunberg, 'Pawn Star' Rick Harrison Kick Off 'Talk About It for Epilepsy!' Netathon Presented by Epilepsy Foundation and Sunovion
-
'Heroes' Actor Greg Grunberg, 'Pawn Star' Rick Harrison to Co-Host 'Talk About It for Epilepsy!' Presented by Epilepsy Foundation and Sunovion

